Constellation Pharmaceuticals INC: insider trades · United States · SEC (Form 4)

About Constellation Pharmaceuticals INC

Constellation Pharmaceuticals Inc. was a U.S.-based biopharmaceutical company that traded on the Nasdaq Global Select Market under the ticker CNST, placing it squarely in the U.S. public equity market rather than a non-U.S. venue. The company was founded in 2008, originally incorporated as EpiGenetiX, Inc., and later renamed Constellation Pharmaceuticals, Inc. in March 2008. Its principal headquarters were in Cambridge, Massachusetts, and the company later planned a relocation to Watertown, Massachusetts. From an investor perspective, this was a classic U.S. clinical-stage biotech story: science-led, capital-intensive, and highly dependent on clinical execution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1434418/000156459021007783/cnst-10k_20201231.htm?utm_source=openai)) Constellation’s core business was epigenetics-driven oncology drug development. The company focused on discovering and advancing novel therapeutics for cancers linked to abnormal gene expression and treatment resistance. It did not operate as a diversified commercial pharma platform; rather, value creation came from research and development, clinical milestones, and the potential for strategic partnering or acquisition. Its best-known programs included CPI-0610, later named pelabresib, an oral BET inhibitor studied in myelofibrosis and other hematologic malignancies, as well as CPI-0209, another oncology candidate in its pipeline. This focus gave the company a differentiated scientific profile in a crowded oncology landscape. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1434418/000156459021007783/cnst-10k_20201231.htm?utm_source=openai)) In competitive terms, Constellation operated in a highly contested segment of biotechnology, facing competition from both large pharmaceutical companies and specialized oncology developers. Its competitive edge was its epigenetics platform and its targeted approach to hard-to-treat cancers, especially patient populations with limited response to existing therapies. That said, as with most clinical-stage companies, its risk profile was elevated: financing needs, trial outcomes, regulatory review, and commercial uncertainty were all material. The investment case was therefore tied more to pipeline optionality than to current product revenue. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1434418/000156459021007783/cnst-10k_20201231.htm?utm_source=openai)) The most important recent corporate event was the company’s acquisition by MorphoSys, completed in July 2021. MorphoSys launched a cash tender offer at $34.00 per share and then completed a second-step merger, taking Constellation private as an indirect wholly owned subsidiary and removing CNST from the Nasdaq. For current market readers, this is crucial context: Constellation is no longer an independent listed issuer, so any Form 4 references to CNST are historical rather than reflective of an active standalone equity story. ([marketscreener.com](https://www.marketscreener.com/quote/stock/CONSTELLATION-PHARMACEUTI-44979177/news/Constellation-Pharmaceuticals-Completion-of-Acquisition-or-Disposition-of-Assets-Form-8-K-35869598/?utm_source=openai)) Overall, Constellation Pharmaceuticals was a U.S. epigenetics-focused oncology biotech founded in 2008, headquartered in Cambridge, Massachusetts, listed on Nasdaq, and built around a specialized clinical pipeline. Its legacy is that of a scientifically credible but ultimately transaction-driven company absorbed before reaching full commercial maturity. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1434418/000156459021007783/cnst-10k_20201231.htm?utm_source=openai))